AbCellera Biologics
ABCL
144 hedge funds and large institutions have $371M invested in AbCellera Biologics in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 50 increasing their positions, 38 reducing their positions, and 27 closing their positions.
128% more call options, than puts
Call options by funds: $7.01M | Put options by funds: $3.07M
32% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 38
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
2% more funds holding
Funds holding: 141 → 144 (+3)
1.4% more ownership
Funds ownership: 34.81% → 36.22% (+1.4%)
29% less capital invested
Capital invested by funds: $525M → $371M (-$154M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$35.2M |
| 2 |
Goldman Sachs
New York
|
+$18.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.13M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$4.76M |
| 5 |
Jane Street
New York
|
+$4.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$52.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$13.1M |
| 3 |
Renaissance Technologies
New York
|
-$4.34M |
| 4 |
DnB Asset Management
Oslo,
Norway
|
-$3.3M |
| 5 |
Millennium Management
New York
|
-$2.93M |
ABCL Hedge Fund Activity: Q4 2025 in Review
144 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q4 2025, worth a combined $371M — down 29% from $525M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ABCL positions and 27 closed out — a net gain of 4 holders — while 50 added to existing stakes and 38 trimmed.
The largest buyer was UBS AM, opening a new position worth an estimated $35.2M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $52.4M sold.
- 144 institutional investors held AbCellera Biologics (ABCL) as of Q4 2025, up from 141 in Q3 2025.
- Funds reported $371M of AbCellera Biologics stock for Q4 2025, down 29% quarter-over-quarter.
- 31 funds opened new AbCellera Biologics positions in Q4 2025 and 27 closed out, a net change of +4 holders.
- The largest AbCellera Biologics buyer in Q4 2025 was UBS AM, an estimated $35.2M added.
- The largest AbCellera Biologics seller in Q4 2025 was Baillie Gifford & Co, an estimated $52.4M sold.
Based on aggregated 13F filings for Q4 2025.